Primary Liver Cancer
Conditions
Keywords
primary liver cancer, clinical features
Brief summary
Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC.
Detailed description
Primary liver cancer (PLC) is the sixth most common malignancy in the world and the third most common cause of malignancy death. PLC mainly includes hepatocellular carcinoma (75%-85%) and intrahepatic cholangiocarcinoma (10%-15%). In 2020, there were about 905,677 new cases of PLC worldwide, and 830,180 deaths. Despite the availability of a variety of treatments for PLC, the 5-year net survival rate is still only 5% to 30%. How to effectively reduce the disease burden of PLC is a major public health problem that needs to be solved worldwide. Common risk factors for PLC include Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection, alcohol consumption, metabolic factors, etc. Although antiviral drugs can control or even cure chronic HBV and HCV to a certain extent, chronic viral infection is still the leading cause of PLC worldwide. In addition, with the prevalence of obesity, diabetes and non-alcoholic fatty liver disease (NAFLD), the incidence of non-infectious PLC is gradually increasing. In recent years, NAFLD has gradually become the leading cause of liver transplant waiting list for patients with hepatocellular carcinoma in the United States. The clinical characteristics and prognosis of PLC caused by different pathogenic factors are different. Therefore, it is of great significance to fully identify the risk factors of PLC, be familiar with the clinical characteristics and prognosis of disease development, and understand the relevant monitoring and follow-up strategies for the prevention and treatment of PLC. Currently, there are few large, single-center cohort studies on the clinical features and long-term prognosis of PLC.
Interventions
None listed
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years or older; 2. initial diagnosis of primary liver cancer based on enhanced CT or enhanced MRI or pathology
Exclusion criteria
1. other types of malignant tumors; 2. mental illness, severe cardiopulmonary dysfunction, severe renal insufficiency, serious infection and cerebrovascular accident; 3. received liver transplant or other organ transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Epidemiological characteristics of overall cohort by liver disease etiology | 0 year | Epidemiological characteristics of overall cohort by liver disease etiology, including HBV, HCV, NAFLD, ALD and others. |
| Clinical characteristics of overall cohort by liver disease etiology | 0 year | Clinical characteristics of overall cohort by liver disease etiology, including HBV, HCV, NAFLD, ALD and others. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival rates of overall cohort and different etiologies | 1 year, 3years，10 years | 1-year, 3-year, 5-year, and 10-year survival rates for overall cohort and different etiologies |
| Risk factors of prognosis in overall cohort and different etiologies | 10 years | Risk factors for recurrence, metastasis, and all cause death in overall cohort and different etiologies |
Countries
China
Contacts
Primary ContactJie Li, M.D.,Ph.D
Backup ContactQianqian Chen
Outcome results
None listed